We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...
Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical...
EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -1.88679245283 | 1.06 | 1.09 | 1.03 | 117353 | 1.0535794 | CS |
4 | -0.01 | -0.952380952381 | 1.05 | 1.09 | 1.01 | 185277 | 1.05311874 | CS |
12 | -1.47 | -58.5657370518 | 2.51 | 3.07 | 0.87 | 632452 | 1.1554423 | CS |
26 | -2.06 | -66.4516129032 | 3.1 | 3.185 | 0.87 | 399494 | 1.51044179 | CS |
52 | -13.62 | -92.9058663029 | 14.66 | 22.22 | 0.87 | 328410 | 3.63120858 | CS |
156 | -15.81 | -93.8278931751 | 16.85 | 23.58 | 0.87 | 166543 | 5.42737872 | CS |
260 | -15.81 | -93.8278931751 | 16.85 | 23.58 | 0.87 | 166543 | 5.42737872 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions